VTGN · VistaGen Therapeutics, Inc.

Vistagen Therapeutics has reached a critical milestone with the completion of the last patient visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, its Phase 3 trial evaluating fasedienol nasal spray for acute treatment of social anxiety disorder using a public speaking challenge and SUDS primary endpoint. This U.S. multi-center study advances the company's pherine pipeline, which targets nose-to-brain neurocircuitry without systemic absorption, potentially offering rapid-onset anxiolytic effects with reduced side effect risks compared to benzodiazepines. Topline results are anticipated in Q2 2026, a pivotal catalyst for investors as positive data, combined with prior PALISADE-2 results, could support an NDA submission to the FDA. The open-label extension allows participants up to six daily doses for 12 months, providing long-term safety data. Vistagen refined the SAP based on analyses of PALISADE-1, -2, and -3 datasets using AI/ML, incorporating pre-dose SUDS as a baseline covariate—aligned with FDA's 2023 guidance on covariates in RCTs—with no FDA objections and no protocol changes. Fast Track designation underscores regulatory support. CEO Shawn Singh highlighted the step's importance for the program. Success here could validate fasedienol's differentiated MOA for a disorder affecting over 30 million U.S. adults, positioning Vistagen for commercialization in a high-need area.